169.97
-8.23 (-4.62%)
| 前收盘价格 | 178.20 |
| 成交量 | 710,600 |
| 预期市盈率 (P/E Forward) | 64.12 |
| 价格/销量 (P/S) | 12.50 |
| 股市价格/股市净资产 (P/B) | 4.83 |
| 52周波幅 |
| 营业毛利率 | -3.53% |
| 营业利益率 (TTM) | 5.59% |
| 稀释每股收益 (EPS TTM) | -0.420 |
| 季度收入增长率 (YOY) | 10.40% |
| 季度盈利增长率 (YOY) | 76.90% |
| 总债务/股东权益 (D/E MRQ) | 34.44% |
| 流动比率 (MRQ) | 6.79 |
| 营业现金流 (OCF TTM) | 145.69 M |
| 杠杆自由现金流 (LFCF TTM) | 183.66 M |
| 资产报酬率 (ROA TTM) | 0.92% |
| 股东权益报酬率 (ROE TTM) | -1.16% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 混合的 | 混合的 |
| Medical Instruments & Supplies (全球的) | 混合的 | 混合的 | |
| 股票 | Repligen Corporation | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.3 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -0.5 |
| 相对估值 | NA |
| 财务健康 | 2.0 |
| 宏观环境 | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.75 |
|
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively. |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Small Core |
| 内部持股比例 | 6.41% |
| 机构持股比例 | 105.07% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| United Capital Financial Advisors, Llc | 30 Jun 2026 | 2,790,650 |
| Maverick Capital Ltd | 30 Jun 2026 | 1,984,554 |
| Holocene Advisors, Lp | 30 Jun 2026 | 1,292,191 |
该时间范围内无数据。
该时间范围内无数据。
投资组合